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Across countries, a small group of patients accounts for the majority of health care spend-
ing. These patients are more likely than other patients to experience problems with quality
and safety in their care, suggesting that efforts targeting efficiency and quality among this
population might have significant payoffs for health systems. Better understanding of simi-
larities and differences in patient characteristics and health care use in different countries
may ultimately inform further efforts to improve care for HNHC patients in these health
systems.
Methods
We conducted a cross-sectional descriptive study using one year of patient-level data on
high-cost patients in seven high-income OECD member countries. Countries were selected
based on availability of detailed information (large enough samples of claims, administra-
tive, and survey data of high-cost patients). We studied concentration of spending among
high-cost patients, characteristics of high-cost patients, and per capita spending on high-
cost patients.
Findings
Cost-concentration of the top 5% of patients varied across countries, from 41% in Japan to
60% in Canada, driven primarily by variation in the top 1% of spenders. In general, high-cost
patients were more likely to be female (57.7% on average), had a significant number of
multi-morbidities (up to on average 10 major diagnostic categories (ICD chapters), and had
a lower socioeconomic status. Characteristics of high-cost patients varied as well: median
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Data Availability Statement: Our study uses third
party data sources from the seven countries; In
Canada and Spain, datasets are owned by
government-funded regional bodies. In Germany,
data were obtained from and owned by two
statutory health insurers. In the Netherlands data
are owned by one private, not for profit, health
insurer. Japanese data are owned by two
prefectures of insurance claims. English data come
from the Clinical Practice Research Datalink). US
data are obtained from the Medical Expenditure
Panel Survey, these data are freely available online
age ranged from 62 in the Netherlands to 75 in Germany and the difference in socioeco-
nomic status is particularly stark in the US. Lastly, utilization, particularly for inpatient care,
varied with an average number of inpatient days ranging from 6.6 nights (US) to 97.7 nights
in Japan.
Interpretation
In this descriptive study, there is substantial variation in the cost concentration, characteris-
tics, and per capita spending on high-cost patient populations across high-income countries.
Differences in the way that health systems are structured likely explains some of this varia-
tion, which suggests the potential of cross-system learning opportunities. Our findings high-
light the need for further studies including comparable performance metrics and institutional
analysis.
Introduction
Health care spending is concentrated among a relatively small number of high-cost patients
[1]. These patients face the most pressing medical needs and typically suffer poor clinical out-
comes [2–4]. It has been suggested that improved care for this population could increase effi-
ciency and improve overall quality within health systems [5].
Prior studies found that high need, high cost (HNHC) patients tend to be older and tend to
suffer from more morbidities than the general population [6–9]. However, we do not know
how generalizable this phenomenon is across health systems and what the impact of a health
system may be on characteristics and health care use. To date, no study has systematically
described HNHC patients across different countries, using patient-level data inclusive of all
age groups. A cross-country descriptive comparison of HNHC patients could help us to move
beyond assumptions and identify similarities as well as differences in patterns that may inform
further efforts to improve care for HNHC patients.
Therefore, we sought to describe the top 5% of patients with the highest medical spending
in a given year in seven countries: Canada, England, Germany, Japan, the Netherlands, Spain
and the United States. Our research questions were: What are the demographic and clinical
characteristics of the top 5% highest spending patients? What is the concentration of spending
in top-1% and top-5% high-cost patients? And, what are the differences in healthcare utiliza-
tion patterns across these countries?
The goal of this research is to better understand the characteristics and healthcare utiliza-
tion of high-cost populations indifferent health system to facilitate the identification of priori-
ties for future research and action. In addition, this work provides a preliminary exploration of
the impact of differing health systems on HNHC and the care they receive.
Study data and methods
Ethical committees
This research involved anonymised records and data sets available for analysis. In each coun-
try, appropriate permissions have already been obtained from data holders, and it was not
possible to identify individuals from the information provided. Therefore, this study was con-
sidered exempt from ethical approval. With the exception of Japan, where this study was
approved by the Ethics Committee of Kyoto University Graduate School and Faculty of
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(https://meps.ahrq.gov/mepsweb/). Primary
relevant data are within the manuscript and its
Supporting Information files. The access to data
supporting the manuscript findings is restricted in
accordance with data sharing regulations within
and across countries. These policies require that
access to data be limited to persons who require
such access to perform their role on an approved
Project or Third-Party Project. Additional
information on the data sources used in this study
is in the Supporting Information S1 File. Truncated
aggregated data may be accessed upon request,
inquiries for data can be sent to the author of the
manuscript.
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Medicine, Japan (R0438-1) and Aragon, Spain where the study was approved by the regional
Ethics Committee of Aragon (PI17/0411).
Study design, data sources and study sample
We conducted a retrospective observational study of the top 5% high-cost patients in one year
in seven high-income countries, Canada, England, Germany, Japan, the Netherlands, Spain,
and the United States. Country partners were recruited based on high-quality sources of
patient level activity based administrative claims data, survey data, electronic medical records
and/or available registry data. Our primary concern with respect to data was ensuring ade-
quate sample sizes to permit reasonable inference about the use of individuals’ medical ser-
vices. We ensured that the samples included all medical care received by beneficiaries across
all age groups, and in the US across all payers.
We used a variety of rich data sources for our analysis. In Canada and Spain, the dataset
included all claims from all inhabitants in one region, Ontario and Aragon, respectively.
In Germany, data were obtained from two statutory health insurers, whose population
is generally more rural and older than the national average. In the Netherlands, high-cost
analyses were conducted on all beneficiaries of one insurance company, offering a sample
of 20% of the population. Japanese data came from two prefectures of insurance claims of
those not currently employed (e.g. farmers, the self-employed, retired, unemployed and
their families). (Note: we address concerns of generalizability of this data in the Appendix,
see S1 File). In England, we used a database from selected primary care practices (Clinical
Practice Research Datalink) that is representative for the population and enriched this infor-
mation with standardized prices. For the U.S., we relied on utilization and payment data
from the Medical Expenditure Panel Survey (MEPS). This is a is a set of large-scale surveys of
families and individuals, their medical providers, and employers across the United States.
MEPS is considered the most complete source of data on health care utilization in the U.S.
and is designed to be representative of the non-institutionalized, community-dwelling
population.
The appendix contains a more detailed description of the data sources as well as informa-
tion on the health care systems and demographics for each country (see S1 File).
We first identified individuals falling into the top 5% (the so-called ‘high-cost’ population)
of medical care spending in each country. We did not exclude those individuals with no medi-
cal spending in a given year. Activities were costed in each country using a standard approach,
generally price times volume, and if pertinent, standardized for between payer and between
provider price differences (See S1 File, paragraph 2.7.2).
Costs were categorized according to the International Classification for Health Accounts
(ICHA-HC) categories for Inpatient Curative Care (HC1.1); Day and Outpatient Care (HC1.2
and HC1.3, this includes primary care); Rehabilitative and Post-Acute Care (HC2); Outpatient
pharmaceuticals (HC5.1.1 and HC5.1.2); and, Other Medical Goods and Ancillary Services
(HC5.1.3, HC5.2 and HC4) [10]. A total of 43 country-specific categories of spending were
mapped to these ICHA categories. While this substantially coarsens the data, it is a necessary
simplification to permit cross-country comparison. Additionally, this mapping was straight-
forward in most cases. For instance, all pharmaceuticals and drugs were categorized into a sin-
gle category, the use of primary care and specialists was categorized as outpatient, and the use
of imaging and lab tests were categorized as “other.” When uncertainties remained, we
reviewed detailed documentation describing expense categories and obtained additional spe-
cific descriptions for the items included. The appendix summarizes the costing method and
classification schemes for each sample (See S1 File). To permit between-country comparisons,
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measures of spending were adjusted for purchasing power parity (PPP) to account for differ-
ences in cost-of-living and purchasing power between countries [11].
Clinical conditions were described using International Classification of Diseases, tenth
revision (ICD-10) codes in all countries except Spain and the U.S., where comparable clinical
classification codes (CCC) were used. Prescription drug utilization was classified using the
Anatomical Therapeutic Chemical (ATC) Classification System categories, level 2, except for
Japan where no official mapping scheme to the ATC was available, and England where equiva-
lent British National Formulary sections were used.
Analyses
We performed descriptive analyses of demographic and clinical characteristics of patients, and
spending and utilization patterns across countries.
We studied relative spending among the high-cost patients between the seven countries
according to the ICHA-HC spending categories and our definition of mental health spending
(see above).
Because we expected inpatient spending to account for the majority of overall spending, we
also examined differences in inpatient admissions and average length of stay.
Study results
Patient characteristics
In all samples, HNHC patients are more likely to be female and have lower socioeconomic sta-
tus. The difference in socioeconomic status is particularly stark in the US (Table 1). The
median age of HNHC patients varies from 62 (Netherlands) to 75 in Germany; and 40% to
68% of HNHC patients are younger than 70. When we categorized HNHC patients into age
groups, we found that older patients in Germany faced a smaller chance of being HNHC than
patients in the US, Canada, and England (Fig 1). The mortality rate of HNHC patients during
the study period ranged from 7% in the Netherlands to 11% in England. Use of prescription
drugs ranged from 8 to 10 distinct categories (excluding England and Japan because of differ-
ence in classification methodology). As might be expected, HNHC patients had significant
comorbidities, with patients in Japan having conditions across nearly 10 unique ICD chapters
(Table 1). The conditions most reported were diseases of the circulatory system (ICD chapter
I00-I99), neoplasms (ICD chapter C00-D49) and musculoskeletal illnesses (ICD chapter
M00-M99).
Cost concentration and spending per patient
Across all countries, medical spending is highly concentrated, although the exact extent of
concentration varies (Fig 2). For instance, in Japan the top 5% of spenders account for
41% of spending, compared to 60% in Canada. These differences appear to be primarily
explained by variation in spending among the top 1%, which ranges from 15% in Japan to
33% in Canada. (Variation in spending among the top 2–5% is much smaller, ranging from
26% to 31%).
Spending and utilization patterns
Inpatient hospital care is consistently the largest spending category across countries (Fig 3),
ranging from 41% of spending in the Netherlands to 73% in Spain. The share of outpatient
and office-based hospital care also varies, ranging from 8% in Spain to 37% in England.
‘High-cost’ patients in seven countries
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Similarly, we observe variation in pharmaceutical spending, which accounts for 11% of spend-
ing in Spain and Canada to 23% of spending in Germany. The proportion of spending on
rehabilitation and post-acute care is largest in the US and Canada, and highest among the
elderly populations (> 80 years old).
While inpatient spending consistently accounts for a plurality of spending across countries,
we observed substantial variation in use of inpatient services. For instance, the average number
of inpatient stays ranged from 6.6 nights (U.S.) to 97.7 nights in Japan. And while 96% of Span-
ish high-cost patients spent at least 1 night in hospital, only 69% of US HNHC patients do.
(Fig 4) As with overall per capita spending, the US remains the most expensive on the inpatient
front—the average cost of an inpatient night (PPP-adjusted USD), ranges from $432 in Japan
to $3,180 in the U.S.
Table 1. Demographic and clinical characteristics of high-cost patients.
CAN ENG GER JPN NL SP USA
Region Ontario Kinzigtal Aragon
Demographics (top 5%)
% Female 55% 57% 54% 49% 54% 48.90% 56%
Mean age 61 64 68 67 57 67 60
Median age 65 69 75 69 62 71 63
Proportion of patients < 70 years 62% 53% 40% 54% 68% 48.90% 65%
Population mortality rate 8.4% 11.3% 10.8% 9.0% 6.9% 10.3% NA
Mortality rate > 65 14.0% NA 14.7% 12.6% 11.7% 13.9% NA
Socio-economic status (1st is lowest) 1st 22.6% 1st 22.5% NA NA 1st 39.0% 1st 0.1% 1st 33.4%
2nd 20.4% 2nd 21.1% 2nd 34.8% 2nd 77.7% 2nd 21.0%
3rd 19.3% 3rd 20.2% 3rd 26.2% 3rd 22.1% 3rd 17.0%
4th 19.2% 4th 19.1% 4th 0.2% 4th 15.7%
5th 17.9% 5th 17.2% 5th 12.9%
Clinical characteristics (top 5%)
# unique ICD chapters (SD) 6.5 (2.4) 4.1 (2.5) 8.0 (2.9) 9.6 (3.0) 2.5 (1.7) 4.3 (2.4) 5.8 (2.1)
# unique drug codes (SD) 10.0 (4.0) 4.6 (2.1) 9.7 (4.6) 22.6 (11.5) 8.0 (4.8) 8.8 (4.0) 7.8 (4.0)
Spending
Mean Total Cost top 5% $22,588 $13,078 $27,560 $42,170 $28,508 $14,328 $40,825
Mean Total Cost top 1% $61,244 $27,297 $61,855 $78,019 $65,766 $29,526 $79,842
Authors’ analysis of data from administrative claims data from the region of Ontario in Canada (CAN, FY 2012–2013), the Kinzigtal region in Germany (GER, 2013),
two prefectures in Japan (JPN, FY 2014), a national insurer in the Netherlands (NL, 2012), the region of Aragon in Spain (SP, 2015). Data for the United States came
from the Medical Expenditure Panel Survey (US, 2013–2014), and English data from a utilization database from selected primary care practices (Clinical Practice
Research Datalink), linked with information from Hospital Episode Statistics and enriched with cost data. The Appendix (see S1 File) provides a full description of
country- or province-specific data sources. Socio-economic status is ranked from low (1st) to high and based on household individual income level in CAN and US; a
compound score per postal code region based on income and education in NL; compound score (index of multiple deprivation) per small geographical area
(approximately 1,500 residents) in ENG. Results are presented based on quintiles of population in CAN, ENG and US, and tertials in NL. In Spain, a socioeconomic
proxy was based on level of drugs copayment, which in turn is based on household income. 1: no copayment: social salary—long-term unemployment and dole
exhausted; 2: <18,000€ annual income; 3:18,000 to 100,000€ annual income; 4: more than 100,000. GER and JPN did not have access to this information. Unique
chapters International Classification of Diseases 10th revision: chapter R (symptoms and signs) and Z (other) are excluded; In the Netherlands, claims data for primary
care don’t include ICD. International drugs classification using the Anatomical Therapeutical Chemical Classification scheme, level 2 (93 categories), except for Japan
and England. In Japan, the National Health Insurance Drug List was used (first 3 digits, 142 classifications), In England equivalent BNF sections were used for primary
care prescriptions only. Total spending is based on all medical care. Long-term care and custodial services are excluded. Results are reported in purchasing power parity
(PPP)-adjusted USD, adjusting for exchange rate instead of PPP gives similar results. The English dataset did not have the following components available: community
care, mental health and some other secondary and primary care and so underestimate total cost by approximately 35%.
https://doi.org/10.1371/journal.pone.0217353.t001
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Discussion and implications
Discussion
This study represents the first systematic study describing high-cost patients using high-qual-
ity, patient-level data in large samples across different countries. We find that these patients
are generally older, more often female, and struggle with several (chronic) conditions. HNHC
patients suffer most frequently from cardiovascular diseases, neoplasms and musculoskeletal
Fig 1. Proportion of high-cost patients as percentage of total population. Notes: Authors’ analysis of administrative
or survey data for each region. The Appendix provides a full description of country- or province-specific data sources
(see S1 File). Abbreviated countries are Canada, England, Germany, Japan, the Netherlands, Spain and United States.
We do not have information for the Netherlands.
https://doi.org/10.1371/journal.pone.0217353.g001
Fig 2. Proportion of medical spending by percentage of population. Notes: Authors’ analysis of administrative or
survey data for each region. The Appendix provides a full description of country- or province-specific data sources (see
S1 File). Abbreviated countries are Canada, England, Germany, Japan, the Netherlands, Spain and United States.
Analyses are based on all medical care. Long-term care and custodial services are excluded.
https://doi.org/10.1371/journal.pone.0217353.g002
‘High-cost’ patients in seven countries
PLOS ONE | https://doi.org/10.1371/journal.pone.0217353 June 19, 2019 6 / 11
disorders. Characteristics of these patients vary across countries in terms of absolute spending,
hospital utilization patterns, and the distribution of spending by category.
Our findings document some, but not substantial variation in concentration among the top
5% of spenders. Additionally, this variation in cost concentration is almost entirely driven by
the top 1% high cost patients. There may be several explanations: First, this group is more
likely to use more specific resource-intensive treatments such as very expensive technologies
[6]. Indeed, prior research has shown that variation in spending appears to be largely driven
by variation in the use of medical technology and health care prices [12], and that the highest
prices for labor and goods are found in the U.S. [13,14]. Our findings on the costs of an inpa-
tient day seem to support this: the relatively low rate of hospitalizations, compared with high
Fig 3. Distribution of medical spending. Notes: Authors’ analysis of administrative or survey data for each region.
The Appendix provides a full description of country- or province-specific data sources (see S1 File). Abbreviated
countries are Canada, England, Germany, Japan, the Netherlands, Spain and United States. Outpatient spending refers
to primary care, outpatient specialist care and day curative care except in Germany, where outpatient surgeries and day
care is included in the inpatient category. Rehabilitation refers to all rehabilitative care, both inpatient and outpatient
(home health). Missing data; ENG, rehab, other; JPN, other; SP, rehab.
https://doi.org/10.1371/journal.pone.0217353.g003
Fig 4. Utilization: Inpatient admissions to hospital. Notes: SOURCE Authors’ analysis of administrative or survey
data for each region. The Appendix provides a full description of country- or province-specific data sources (see S1
File). Abbreviated countries are Canada, England, Germany, Japan, the Netherlands, Spain and United States. The
average number of inpatient days for top 5% high cost population. Inpatient days are defined as the number of nights a
patient stays in the hospital. For Canada: �Including both DAD & OMHRS visits.
https://doi.org/10.1371/journal.pone.0217353.g004
‘High-cost’ patients in seven countries
PLOS ONE | https://doi.org/10.1371/journal.pone.0217353 June 19, 2019 7 / 11
per unit costs in the U.S. may suggest that further reductions in volume may be less feasible,
and that price is a more logical target for interventions.
Limitations
Our results come with some caveats. Although we undertook substantial efforts to achieve a
fair degree of data comparability between countries, the restrictions in data sharing within and
across countries, impeded the estimation of proper risk-adjusted measures of HNHC patients’
utilization, so the exercise should be confined to a thorough description of the utilization and
associated costs for groups of fragile patients in across health systems, not a full comparison of
health systems performance. A resulting limitation of this approach was that our analyses were
limited to those indicators with highest comparability [15] and that more detailed information
within utilization categories, such as the use of diagnostic tests or emergency care. Also, we
were not able to assess the impact of medical conditions or the use of specific pharmaceuticals.
Additionally, as costs computing methodologies varied between countries (eg, full costing
methods, imputation, estimations based on public tariffs) the overall costs might not be
directly comparable. Moreover, most of the regions only include third-party financing, so pri-
vate payments and out-of-pocket costs are generally not considered. Although in most of our
sample of countries these payments are thought to amount for only a small proportion of med-
ical spending in this type of patients, it is uncertain the actual effect.
To see whether our overall expenditure estimations were affected by these limitations,
we ranked each country overall expenditure per-capita in HNHC and compared with
OECD spending rankings. Notably we got the same ranking for all countries except Japan
where just two prefectures were included in the sample. All in all, having different cost-allo-
cation methods has very likely limited the interpretation of differences across spending
categories.
On a different line, because our analyses contain one full year of spending, we are able to
give a complete overview of high-cost users in any given year, but further analysis is needed to
analyse the differences between persistent high-cost users and incidental high-cost users.
Lastly, although sufficiently large, the samples used in our study might not be representative
of the universe of HNHC patients then limiting the generalizability of our findings.
Implications and conclusion
Given that a small share of the population accounts for a substantial plurality of medical
spending, improving outcomes and reducing costs requires strategies that focus on these
patients. To do so, analyses like ours are prerequisites.
We show that these patients, regardless of health system, suffer from multiple co-morbidi-
ties. Prior research suggests that these patients face gaps in care [16], and that lack of care coor-
dination increases health care utilization [17–19]. While it is an open question to what extent
better coordination can reduce spending broadly [20], evidence suggests that targeted care
coordination programs do increase quality and may reduce costs for specific populations [21–
23]. This suggests that better coordination of care before, during and after an inpatient admis-
sion may be beneficial.
The heterogeneity of populations within the HNHC group hampers the development of evi-
dence-based strategies to improve conditions for these patients and increase system efficiency.
On the other hand, because the patient characteristics of the high-cost patient group appears
to be more similar than different across countries may suggest that the differences can be
explained by the differences in the organization of different health care systems. Thus, more
research focusing on identifying homogenous patient groups within the top 5% highest
‘High-cost’ patients in seven countries
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spenders and study their care pathways may yield many opportunities to identify promising
ways for improvements. Additionally, cross-country comparisons also can help because they
create larger populations solving possible small-n diseases.
In conclusion, this is the first study, and based on patient level data, which systematically
describes HNHC patients across countries. Our findings and the limitations highlight the need
for sounder cross-national comparisons of high-cost, high-need patients using prospectively
designed quality and cost metrics, including more specific information on (combinations of)
medical conditions and health care use, institutional analysis, and risk-adjustment or stratifica-
tion of individuals. Further work along these lines hold strong promise to improve patients’
lives as well as systems’ performance. Ultimately, the results of this project provide input for
countries to prioritize policy targets to improve care for their high-cost population.
Transparency & author statement
The lead author (the manuscript’s guarantor) affirms that the manuscript is an honest, accu-
rate, and transparent account of the study being reported; no important aspects of the study
have been omitted; and any discrepancies from the study as originally planned (and, if rele-
vant, registered) have been explained.
All authors agree to be accountable for all aspects of the work and approved the final manu-
script for submission.
Supporting information




Conceptualization: Marit A. C. Tanke, Yevgeniy Feyman, Enrique Bernal-Delgado, Sarah R.
Deeny, Patrick Jeurissen, Michael Schull, Joost J. G. Wammes, Walter P. Wodchis, Gregg S.
Meyer.
Data curation: Enrique Bernal-Delgado.
Formal analysis: Marit A. C. Tanke, Yevgeniy Feyman, Sarah R. Deeny, Yuichi Imanaka,
Laura Lange, Alexander Pimperl, Noriko Sasaki, Joost J. G. Wammes, Walter P. Wodchis.
Funding acquisition: Marit A. C. Tanke.
Investigation: Marit A. C. Tanke, Yevgeniy Feyman.
Methodology: Marit A. C. Tanke, Yevgeniy Feyman, Enrique Bernal-Delgado, Sarah R.
Deeny, Yuichi Imanaka, Patrick Jeurissen, Alexander Pimperl, Michael Schull, Walter P.
Wodchis, Gregg S. Meyer.
Project administration: Marit A. C. Tanke.
Resources: Marit A. C. Tanke, Yuichi Imanaka, Patrick Jeurissen, Laura Lange, Alexander
Pimperl, Noriko Sasaki, Joost J. G. Wammes, Walter P. Wodchis.
Software: Marit A. C. Tanke.
Supervision: Marit A. C. Tanke, Patrick Jeurissen, Michael Schull, Walter P. Wodchis, Gregg
S. Meyer.
‘High-cost’ patients in seven countries
PLOS ONE | https://doi.org/10.1371/journal.pone.0217353 June 19, 2019 9 / 11
Validation: Marit A. C. Tanke, Gregg S. Meyer.
Visualization: Marit A. C. Tanke.
Writing – original draft: Marit A. C. Tanke, Yevgeniy Feyman, Enrique Bernal-Delgado,
Sarah R. Deeny, Patrick Jeurissen, Laura Lange, Michael Schull, Joost J. G. Wammes, Wal-
ter P. Wodchis, Gregg S. Meyer.
Writing – review & editing: Marit A. C. Tanke, Yevgeniy Feyman, Enrique Bernal-Delgado,
Sarah R. Deeny, Patrick Jeurissen, Michael Schull, Joost J. G. Wammes, Gregg S. Meyer.
References
1. French E, Kelly E. Medical Spending around the Developed World. Fisc Stud. 2016; 37(3–4):327–44.
2. Alexandre LM. High-cost patients in a fee-for-service medical plan. The case for earlier intervention.
Med Care. 1990; 28(2):112–23. PMID: 2105413
3. Coughlin TA, Long SK. Health care spending and service use among high-cost medicaid beneficiaries,
2002–2004. Inquiry. 2009; 46(4):405–17. PMID: 20184167
4. Aleckxih L, Shen S, Chan I, Taylor D, Drabek J. Individuals Living in the Community with Chronic Condi-
tions and Functional Limitations: A Closer Look. Lewin Group. Washington D.C.; 2010.
5. Blumenthal D, Chernof B, Fulmer T, Lumpkin J, Selberg J. Caring for High-Need, High-Cost Patients—
An Urgent Priority. NEJM. 2016;
6. Wammes JJG, Tanke MA, Jonkers W, Westert GP, Van der Wees P, Jeurissen PP. Characteristics
and healthcare utilisation patterns of high-cost beneficiaries in the Netherlands: a cross-sectional claims
database study. BMJ Open. 2017; 7(11):e017775. https://doi.org/10.1136/bmjopen-2017-017775
PMID: 29133323
7. Wodchis WP, Austin PC, Henry DA. A 3-year study of high-cost users of health care. CMAJ. 2016; 188
(3):182–8. https://doi.org/10.1503/cmaj.150064 PMID: 26755672
8. Calver J, Brameld KJ, Preen DB, Alexia SJ, Boldy DP, McCaul KA. High-cost users of hospital beds in
Western Australia: a population-based record linkage study. Med J Aust. 2006 Apr 17; 184(8):393–7.
PMID: 16618238
9. Riley GF. Long-term trends in the concentration of medicare spending. Health Aff. 2007; 26(3):808–16.
10. OECD, Eurostat, WHO. A System of Health Accounts. 2011.
11. Organization for Economic Co-operation and Development. Purchasing power parities (PPP). 2017
[cited 2017 Jun 12]. https://data.oecd.org/conversion/purchasing-power-parities-ppp.htm
12. Papanicolas I, Woskie LR, Jha AK. Health Care Spending in the United States and Other High-Income
Countries. JAMA. 2018 Mar 13; 319(10):1024. https://doi.org/10.1001/jama.2018.1150 PMID: 29536101
13. Dieleman JL, Squires E, Bui AL, Campbell M, Chapin A, Hamavid H, et al. Factors Associated With
Increases in US Health Care Spending, 1996–2013. JAMA. 2017; 318(17):949–54.
14. Papanicolas I, Jha AK. Challenges in International Comparison of Health Care Systems. JAMA. 2017
Jul 27; 148(8):956–7.
15. Schreyo¨gg J, Stargardt T, Velasco-Garrido M, Busse R. Defining the “health benefit basket” in nine
European countries: Evidence from the European Union Health BASKET Project. Eur J Heal Econ.
2005; 6(SUPPL. 1):2–10.
16. Schoen C, Osborn R, Squires D, Doty M, Pierson R, Applebaum S. New 2011 Survey of Patients With
Complex Care Needs in Eleven Countries. Health Aff. 2011; 30(12):2437–48.
17. Druss BG, Marcus SC, Olfson M, Tanielian T, Elinson L, Pincus HA. Comparing the national economic
burden of five chronic conditions. Heal Aff. 20(6):233–41.
18. Nyweide DJ, Anthony DL, Bynum JPW, Strawderman RL, Weeks WB, Casalino LP, et al. Continuity of
care and the risk of preventable hospitalization in older adults. JAMA Intern Med. 2013; 173(20):1879–
85. https://doi.org/10.1001/jamainternmed.2013.10059 PMID: 24043127
19. Hansen J, Groenewegen PP, Boerma WGW, Kringos DS. Living in a country with a strong primary care
system is beneficial to people with chronic conditions. Health Aff. 2015; 34(9):1531–7.
20. McWilliams JM. Cost Containment and the Tale of Care Coordination. N Engl J Med. 2016; 375
(23):2218–20. https://doi.org/10.1056/NEJMp1610821 PMID: 27959672
21. Blumenthal D, Abrams MK. Tailoring Complex Care Management for High-Need, High-Cost Patients.
JAMA—J Am Med Assoc. 2016; 316(16):1657–8.
‘High-cost’ patients in seven countries
PLOS ONE | https://doi.org/10.1371/journal.pone.0217353 June 19, 2019 10 / 11
22. Hsu J, Vogeli C, Price M, Brand R, Chernew Michael E Mohta N, Chaguturu SK, et al. Substantial
Physician Turnover And Beneficiary “Churn” In A Large Medicare Pioneer ACO. Health Aff. 2017;
36(4):640–8.
23. Melnick GA, Green L, Rich J. House Calls: California Program For Homebound Patients Reduces
Monthly Spending, Delivers Meaningful Care. 2016; 35(1):28–35.
‘High-cost’ patients in seven countries
PLOS ONE | https://doi.org/10.1371/journal.pone.0217353 June 19, 2019 11 / 11
